Search Results - "Armstrong, A.J"

The use of novel PP2A activators in combination with PARP inhibitor for the treatment of high-grade serous ovarian cancer by Armstrong, A.J, Joseph, P, Nagaraj, A.B, Nagel, C.I, Nakayama, J, Waggoner, S.E, Zanotti, K.M, DiFeo, A, Narla, G

Get full text

Impact of Enzalutamide (ENZA) on Patient-Reported Outcomes (PROs) in metastatic Hormone-Sensitive Prostate Cancer (mHSPC) patients with no/low urinary symptoms at baseline: Results from the ARCHES study by Saad, F., Armstrong, A.J., Ivanescu, C., Bhadauria, H., Ramaswamy, K., Morlock, R., Tombal, B.

Get full text

Impact of Prior Radiation Treatment on Sipuleucel-T Product Parameters in PROCEED Patients by Furay, A, Nordquist, L.T, Dakhil, S.R, Green, N.B, Heath, E.I, Tutrone, R.F, Vogelzang, N.J, Armstrong, A.J, Cooperberg, M.R, Tyler, R.C, Whitmore, J.B, Higano, C.S

Get full text

Studying Earthworms (Annelida: Oligochaeta) in South Africa by Nxele, T.C, Lamani, S, Measey, G.J, Armstrong, A.J, Plisko, J.D, Willows-Munro, S, Janion-Scheepers, C, Wilson, J.R.U

“…Earthworms are an important component of southern African invertebrate diversity, due both to their influential roles in soil ecosystems, and the relatively…”
Get full text

Characteristics and outcomes of women with gynecologic cancers undergoing heated intraperitoneal or intrathoracic chemotherapy by Kathawa, C.A., Dominick, C., Armstrong, A.J.

Get full text

Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide by Noonan, K.L., North, S., Bitting, R.L., Armstrong, A.J., Ellard, S.L., Chi, K.N.

“…Abiraterone acetate and enzalutamide both improve outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC). Optimal sequencing for…”
Get full text

Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting by Antonarakis, E S, Armstrong, A J, Dehm, S M, Luo, J

“…While there are myriad mechanisms of primary and acquired resistance to conventional and next-generation hormonal therapies in prostate cancer, the potential…”
Get full text

1781P Health-related quality of life (HRQoL) deterioration-free survival (DetFS) by prostate-specific antigen (PSA) decline in darolutamide (DARO)-treated patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) from ARAMIS by Morgans, A.K., Sweeney, C., Wallis, C., Halabi, S., Armstrong, A.J., Mohamed, A.F., Adorjan, P., Verholen, F., Srinivasan, S., Grimm, M-O.

Get full text

7028 Dasatinib and docetaxel combination treatment for patients with metastatic castration-resistant prostate cancer (CRPC): analysis of Study CA180–086 by Araujo, J, Mathew, P, Armstrong, A.J, Braud, E.L, Posadas, E, Lonberg, M, Gallick, G, Trudel, G.C, Paliwal, P, Logothetis, C.J

Get full text

1365P The impact of PSMA-positive circulating tumor cells in men with metastatic castrate-resistant prostate cancer (mCRPC) by Gupta, S., Yang, Q., Halabi, S., Tubbs, A., Gore, Y., George, D.J., Nanus, D.M., Antonarakis, E.S., Danila, D., Szmulewitz, R., Wenstrup, R.J., Armstrong, A.J.

Get full text

1475P Association of circulating tumor cells (CTCs) with immune checkpoint inhibitor (ICI) responses in metastatic renal cell carcinoma (mRCC) by Zhang, T., Poellmann, M., Park, S-J., Bu, J., Zhao, R., Zhou, Q., Agarwal, A., Parks, J., Reyes-Martinez, M., Armstrong, A.J., George, D.J., Wang, A.Z., Hong, S.

Get full text

1372P Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castration-resistant prostate cancer in the VISION trial by Armstrong, A.J., Sartor, O., Saad, F., Czernin, J., Shore, N.D., Kendi, A.T., Beer, T.M., Vaishampayan, N., El-Haddad, G., Wu, J., Mirante, O., Morris, M.J.

Get full text

1805P Efficacy of olaparib (ola) + abiraterone (abi) vs placebo (pbo) + abi in the non-BRCA mutation (non-BRCAm) subgroup of patients (pts) with metastatic castration-resistant prostate cancer (mCPRC) in the PROpel trial by Mehra, N., Clarke, N.W., Armstrong, A.J., Oya, M., Shore, N.D., Procopio, G., Guedes, J.D.C., Arslan, C., Parnis, F., Brown, E., Schlürmann, F., Joung, J.Y., Sugimoto, M., Choi, Y.D., Castellano, D., Urun, Y., Hosius, C., Desai, C., Degboe, A., Saad, F.

Get full text

1810P Association of health-related quality of life with efficacy outcomes in the VISION study of patients with metastatic castration-resistant prostate cancer by Morris, M.J., Armstrong, A.J., Chi, K.N.N., de Bono, J.S., Herrmann, K., Krause, B., Rahbar, K., Sartor, O., Tagawa, S.T., Nagarajah, J., Wei, X.X., Nordquist, L.T., Koshkin, V.S., Saad, F., Vickers, A., Ghouse, R., Wu, J., Mirante, O., Fizazi, K.

Get full text

Clinical trials for metastatic castrate-resistant prostate cancer—who is looking after the control patients? Questions for the future by Ardolino, L.C., Dear, R., Armstrong, A.J., Gillessen, S., Joshua, A.M.

Get full text

Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer by Armstrong, A.J., Lin, P., Higano, C.S., Sternberg, C.N., Sonpavde, G., Tombal, B., Templeton, A.J., Fizazi, K., Phung, D., Wong, E.K., Krivoshik, A., Beer, T.M.

“…Prognostic models are needed that reflect contemporary practice for men with metastatic castration-resistant prostate cancer (mCRPC). We sought to identify…”
Get full text

A1160 - PROpel: Efficacy of abiraterone + olaparib vs. abiraterone + placebo in the first-line treatment of patients with asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) at baseline by Clarke, N.W., Armstrong, A.J., Thiery-Vuillemin, A., Oya, M., Shore, N., Procopio, G., Guedes, J.D., Arslan, C., Mehra, N., Parnis, F., Brown, E., Schlürmann, F., Joung, J.Y., Sugimoto, M., Sartor, O., Poehlein, C., Barker, L., Degboe, A., Saad, F.

Get full text

PROpel: Efficacy of abiraterone + olaparib vs. abiraterone + placebo in the first-line treatment of patients with asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) at baseline by Clarke, N.W., Armstrong, A.J., Thiery-Vuillemin, A., Oya, M., Shore, N., Procopio, G., Guedes, J.D., Arslan, C., Mehra, N., Parnis, F., Brown, E., Schlürmann, F., Joung, J.Y., Sugimoto, M., Sartor, O., Poehlein, C., Barker, L., Degboe, A., Saad, F.

Get full text

Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL by Graff, J.N., Baciarello, G., Armstrong, A.J., Higano, C.S., Iversen, P., Flaig, T.W., Forer, D., Parli, T., Phung, D., Tombal, B., Beer, T.M., Sternberg, C.N.

“…Prostate cancer disproportionately affects older men. Because age affects treatment decisions, it is important to understand the efficacy and tolerability of…”
Get full text

1398P Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) who received prior androgen deprivation therapy (ADT) and reached low prostate-specific antigen (PSA) levels treated further with enzalutamide (ENZA): Post hoc analyses of ARCHES by Petrylak, D.P., Azad, A.A., Szmulewitz, R.Z., Iguchi, T., Shore, N.D., Holzbeierlein, J., Alekseev, B., El-Chaar, N.N., Rosbrook, B., Ma, J., Zohren, F., Haas, G.P., Stenzl, A., Armstrong, A.J.

Get full text